Literature DB >> 21735097

Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.

Andriy G Golub1, Volodymyr G Bdzhola, Yaroslav V Kyshenia, Vladislav M Sapelkin, Andriy O Prykhod'ko, Olexander P Kukharenko, Olga V Ostrynska, Sergiy M Yarmoluk.   

Abstract

Serine/threonine protein kinase CK2 controls vast variety of fundamental processes in cell life; however, despite long period of study, its functional role is not completely determined. CK2 has a significant pathogenic potential and its activity is strictly associated with the development of various kinds of disorders. There are a growing number of facts that inhibitors of CK2 could be used as pharmaceutical agents for the cancer treatment, viral infections, and inflammatory diseases. In this article, we report structural and biological data on the novel synthetic flavonol derivatives, 3-hydroxy-4'-carboxyflavones, possessing a high inhibitory activity toward CK2. With the aid of combinatorial organic synthesis, molecular modeling techniques and biochemical in vitro tests, we studied the structure-activity relationships of flavonol derivatives and developed binding model describing their key intermolecular interactions with the CK2 ATP-binding site. Obtained data show that the synthetic 3-hydroxy-4'-carboxyflavones possess the highest activity among flavonol inhibitors of CK2 known till date.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735097     DOI: 10.1007/s11010-011-0945-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  32 in total

1.  A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6.

Authors:  Chris Oostenbrink; Alessandra Villa; Alan E Mark; Wilfred F van Gunsteren
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

2.  Modulation of death receptor-mediated apoptosis by CK2.

Authors:  Guixia Wang; Kashif A Ahmad; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

3.  Structural basis of CX-4945 binding to human protein kinase CK2.

Authors:  Andrew D Ferguson; Payal R Sheth; Andrea D Basso; Sunil Paliwal; Kimberly Gray; Thierry O Fischmann; Hung V Le
Journal:  FEBS Lett       Date:  2010-11-18       Impact factor: 4.124

Review 4.  How druggable is protein kinase CK2?

Authors:  Giorgio Cozza; Andrea Bortolato; Stefano Moro
Journal:  Med Res Rev       Date:  2010-05       Impact factor: 12.944

5.  Synthesis, biological evaluation and in silico metabolic and toxicity prediction of some flavanone derivatives.

Authors:  Narayana Subbiah Hari Narayana Moorthy; Rahul Jitendra Singh; Hemendra Pratap Singh; Sayan Dutta Gupta
Journal:  Chem Pharm Bull (Tokyo)       Date:  2006-10       Impact factor: 1.645

6.  Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry.

Authors:  W M Chien; J N Parker; D C Schmidt-Grimminger; T R Broker; L T Chow
Journal:  Cell Growth Differ       Date:  2000-08

7.  Diosgenin inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, NF-kappaB and AP-1 activation.

Authors:  Da-Hye Jung; Hye-Jin Park; Hye-Eun Byun; Yoon-Moon Park; Tae-Wan Kim; Byung-Oh Kim; Sung-Hee Um; Suhkneung Pyo
Journal:  Int Immunopharmacol       Date:  2010-06-11       Impact factor: 4.932

Review 8.  Protein kinase CK2 signal in neoplasia.

Authors:  S Tawfic; S Yu; H Wang; R Faust; A Davis; K Ahmed
Journal:  Histol Histopathol       Date:  2001-04       Impact factor: 2.303

9.  Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis.

Authors:  Masateru Yamada; Susumu Katsuma; Tetsuya Adachi; Akira Hirasawa; Satoshi Shiojima; Tadashi Kadowaki; Yasushi Okuno; Taka-aki Koshimizu; Shigeo Fujii; Yumiko Sekiya; Yohei Miyamoto; Mitsutaka Tamura; Wako Yumura; Hiroshi Nihei; Makio Kobayashi; Gozoh Tsujimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

10.  Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).

Authors:  Stefania Sarno; Erika de Moliner; Maria Ruzzene; Mario A Pagano; Roberto Battistutta; Jenny Bain; Doriano Fabbro; Joseph Schoepfer; Matthew Elliott; Pascal Furet; Flavio Meggio; Giuseppe Zanotti; Lorenzo A Pinna
Journal:  Biochem J       Date:  2003-09-15       Impact factor: 3.857

View more
  4 in total

1.  Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.

Authors:  Mykola V Protopopov; Olga V Ostrynska; Sergiy A Starosyla; Maria A Vodolazhenko; Svetlana M Sirko; Nikolay Yu Gorobets; Volodymyr Bdzhola; Sergey M Desenko; Sergiy M Yarmoluk
Journal:  Mol Divers       Date:  2018-05-29       Impact factor: 2.943

2.  Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.

Authors:  Barbara Guerra; Jennifer Hochscherf; Nina Bjelkerup Jensen; Olaf-Georg Issinger
Journal:  Mol Cell Biochem       Date:  2015-05-12       Impact factor: 3.396

3.  Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor.

Authors:  Karsten Niefind; Nils Bischoff; Andriy G Golub; Volodymyr G Bdzhola; Anatoliy O Balanda; Andriy O Prykhod'ko; Sergiy M Yarmoluk
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-11

4.  Inhibitory influence of natural flavonoids on human protein kinase CK2 isoforms: effect of the regulatory subunit.

Authors:  Andrea Baier; Jolanta Nazaruk; Anna Galicka; Ryszard Szyszka
Journal:  Mol Cell Biochem       Date:  2017-11-29       Impact factor: 3.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.